Price
No data yet.
Social Signal Score
Analyst Ratings
34 analystsRevenue
$3.10B+66.42%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- James E. Davis
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 57,000
- Beta
- 0.55
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 3.82
Financials
Revenue
$3.10B+66.4%Net Income
$312.00M+101.3%EBITDA
$624.00M+83.0%Free Cash Flow
$445.00M+152.8%EPS (diluted)
$2.78+155.0%Shares Outstanding (diluted)
112.00M-20.6%Operating Expenses
$523.00MCash & Debt
$797.00MReturn of Capital
$245.00MRevenue by Segment (annual)
$10.79BDividend per Share
$0.86Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $11.04B | $992.00M | $8.87 |
| 2024 | $9.87B | $871.00M | $7.80 |
| 2023 | $9.25B | $854.00M | $7.59 |
| 2022 | $9.88B | $946.00M | $8.12 |
| 2021 | $10.79B | $2.00B | $15.90 |
| 2020 | $9.44B | $1.43B | $10.68 |
| 2019 | $7.73B | $858.00M | $6.38 |
| 2018 | $7.53B | $736.00M | $5.41 |
| 2017 | $7.71B | $772.00M | $5.63 |
| 2016 | $7.51B | $645.00M | $4.58 |
| 2015 | $7.49B | $709.00M | $4.92 |
| 2014 | $7.43B | $556.00M | $3.83 |
| 2013 | $7.15B | $849.00M | $5.58 |
| 2012 | $7.38B | $555.70M | $3.49 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from DGX's reported EPS growth of 7.4% a year over 13 years.
- EPS in 5 years
- $12.77
- Implied price
- $255.41
- Return from $258.28
- -0.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $126.98 — -50.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| -2.6% | -15.7% | -12.4% | -9.5% | -6.9% | -4.6% |
| 2.4% | -11.4% | -7.9% | -4.9% | -2.2% | 0.3% |
| 7.4% | -7.1% | -3.4% | -0.2% | 2.6% | 5.2% |
| 12.4% | -2.8% | 1.1% | 4.4% | 7.4% | 10.0% |
| 17.4% | 1.6% | 5.6% | 9.1% | 12.2% | 14.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-30.35%Social Signal Score
Mentions (66)
- Newsmarketbeat.com·22h ago·Neutral
Quest Diagnostics Sees Hospital Deal Growth as 2027 Medicare Cuts Loom Quest Diagnostics NYSE: DGX expects continued strength in testing demand and its hospital partnerships, while preparing for a potential revenue hit in 2027 if Medicare laboratory payment cuts take effect, a company representative said during a discussion of the business.
View source ↗ - Newszacks.com·2d ago·Positive
Quest Diagnostics Stock Gains 49.3% YTD: What's Behind the Rally? DGX rises 49.3% YTD, fueled by strong physician and hospital revenues, expanding diagnostics services, strategic acquisitions and higher earnings guidance.
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Quest Diagnostics Incorporated (DGX) Presents at Jefferies Global Healthcare Conference 2026 Transcript Quest Diagnostics Incorporated (DGX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - News (RSS)seekingalpha·6d ago·Neutral
Virtuix outlines $12M STS International LOI as Omni One for Quest drives 55% sequential net sales growth
View source ↗ - Newsprnewswire.com·12d ago·Negative
Quest Diagnostics Declares Quarterly Cash Dividend SECAUCUS, N.J., Nov. 10, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on January 27, 2027, to shareholders of record of Quest Diagnostics common stock on January 12, 2027.
View source ↗ - 4chan /biz/biz·17d ago·Neutral
>>62861246 I don't really see the point Trump will Veto anything for $ Intel has a new node finally ready NVDA has DGX pods and I'm sure OAI/Google/Ant have contingency plans for exactly what just happened. You can deploy these pods in any state real fast within weeks.
View source ↗ - 4chan /biz/biz·20d ago·Neutral
>>62847504 4K games and PCVR with the Quest 3 on my 5070 ti.
View source ↗ - News (RSS)seekingalpha·26d ago·Positive
Quest Diagnostics Upgraded After Strong Q3, While Also Announcing New Test For Alzheimer's
View source ↗ - Newsseekingalpha.com·26d ago·Positive
…For Alzheimer's Quest Diagnostics is upgraded to a strong buy, driven by robust earnings momentum, sector resilience, and sustained outperformance versus benchmarks. DGX delivered its fourth consecutive earnings beat, with Q3 revenue up 10% YoY and EPS up 28.7%, prompting raised full-year guidance. Quest's competitive edge is reinforced by superior margins, a strong ROE above 15%, ongoing innovation, and an investment-grade balance sheet with declining leverage.
View source ↗ - Newsprnewswire.com·30d ago·Neutral
Quest Diagnostics Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Unauthorized Access to Patient Records /PRNewswire/ -- Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from a data breach at Quest Diagnostics, a
View source ↗ - Newsbusinesswire.com·30d ago·Negative
PRIVACY ALERT: AWKO Law LLP Investigates Quest Diagnostics for Data Breach of Patient Records SAN FRANCISCO--(BUSINESS WIRE)--AWKO Law LLP is investigating a data breach that led to unauthorized access to the sensitive information of patients of Quest Diagnostics, a New Jersey-based diagnostic testing company. Quest Diagnostics disclosed in its Securities and Exchange Commission (“SEC”) Form 8-K filing that on October 21, 2026, it identified unauthorized activity in its Quanum Lab Services Manag…
View source ↗ - News (RSS)techcrunch·30d ago·Neutral
Lab testing giant Quest Diagnostics confirms patients’ personal and health data was compromised during breach Quest is the latest in a series of healthcare technology companies that have been hacked in recent months.
View source ↗ - News (RSS)zerohedge·30d ago·Neutral
Tech Layoffs Surge As Corporate America's AI Blitz Raises Fears The Worst Is Yet To Come Tech Layoffs Surge As Corporate America's AI Blitz Raises Fears The Worst Is Yet To Come Bloomberg story counts featuring terms such as "job cuts," "layoffs," and "firings" jumped Thursday to their highest level since early May. The surge in AI-related layoff announcements shows corporate America is ramping up efforts to reduce its workforce and replace humans with chatbots and other AI-related technologies
View source ↗ - Newszacks.com·30d ago·Positive
Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - News (RSS)seekingalpha·31d ago·Positive
Quest Diagnostics Incorporated (DGX) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·31d ago·Positive
DGX Q3 Earnings & Revenues Beat, '26 View Raised, Stock Down in Pre-Market Quest Diagnostics beats Q3 earnings and revenue estimates, raises its 2026 outlook on strong testing demand and margin gains, yet shares dip in pre-market trading.
View source ↗ - Newsmarketbeat.com·31d ago·Positive
What Quest Diagnostics (DGX) Said on Its Q3 Earnings Call Quest Diagnostics NYSE: DGX reported third-quarter 2026 revenue growth of 10% and adjusted earnings-per-share growth of more than 15%, citing demand across its physician, hospital and consumer channels as well as productivity gains from automation and artificial intelligence. The company raised and narrowed its full-year revenue and earnings outlook.
View source ↗ - Newsfool.com·31d ago·Positive
Quest Diagnostics: 3 Key Takeaways for Long-Term Investors Quest Diagnostics expects consumer health revenue growth to exceed 30% in 2026. Organic requisition volume increased 14.4% in the third quarter of 2026.
View source ↗ - Newsseekingalpha.com·31d ago·Positive
Quest Diagnostics Incorporated (DGX) Q3 2026 Earnings Call Transcript Quest Diagnostics Incorporated (DGX) Q3 2026 Earnings Call Transcript
View source ↗ - News (RSS)seekingalpha·31d ago·Positive
Quest Diagnostics Non-GAAP EPS of $3.00 beats by $0.13, revenue of $3.1B beats by $50M
View source ↗ - Newszacks.com·31d ago·Positive
Quest Diagnostics (DGX) Q3 Earnings and Revenues Beat Estimates Quest Diagnostics (DGX) came out with quarterly earnings of $3 per share, beating the Zacks Consensus Estimate of $2.85 per share. This compares to earnings of $2.6 per share a year ago.
View source ↗ - Newsprnewswire.com·31d ago·Positive
….21 and $10.31; and adjusted diluted EPS expected to be between $11.25 and $11.35 SECAUCUS, N.J., Oct. 22, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2026.
View source ↗ - News (RSS)businessinsider·32d ago·Neutral
Quest Diagnostics Q3 2026 Earnings Preview
View source ↗ - News (Marketaux)insidermonkey.com·33d ago·Positive
Quest Diagnostics (DGX): Is Rapid Test Growth Translating Into Better Customer Economics? Quest Diagnostics [+256 characters]
View source ↗ - Newsfastcompany.com·33d ago·Neutral
A new at-home HPV test kit is going national through Quest Diagnostics Patients across the U.S. will soon have access to a new cervical cancer test collected from the comfort of their own home—no stirrups, speculum, or in-person doctor's visit needed.
View source ↗ - News (RSS)investing·38d ago·Neutral
Quest Diagnostics shares may shift 4.4% on Oct. 22 earnings
View source ↗ - News (Marketaux)seekingalpha.com·39d ago·Neutral
IHF: A Concentrated And Volatile ETF In Healthcare Providers (NYSEARCA:IHF) Ticker Name Weight (%) UNH UNITEDHEALTH [+347 characters]
View source ↗ - Newszacks.com·39d ago·Positive
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings DGX heads into Q3 earnings with expected revenue and EPS growth, fueled by strong clinical demand, advanced diagnostics and operational efficiencies.
View source ↗ - Newszacks.com·44d ago·Positive
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newsprnewswire.com·52d ago·Negative
Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials Test showed 100% specificity, with no false-positive results in the cohort, at both 3- and 5-year follow-up, and sensitivity of 100% and 83.3%, respectively, for predicting disease recurrence SECAUCUS, N.J., Oct. 1, 2026 /PRNewswire/ -- A new study published in The Journal of Molecular Diagnostics showed that the Haystack MRD® test is highly accurate at detecting residual
View source ↗ - PodcastAll In·54d ago·Positive
we're going to be able to draw super interesting conclusions about that, not just echo, but the whole healthcare system. Yeah. That's really the bad we're making. Put it in the wearables in there. It's going to be really interesting with the aura as the roots, the fit bits. You start up a watch, you start correlating that data with the blood work. I noticed roof offering labs now through Quest and I don't think, maybe you can sink, you know, you are aura with some of those. But we don't, I haven
View source ↗ - News (RSS)financialpost·58d ago·Neutral
Quest PharmaTech Announces Change of Chief Executive Officer EDMONTON, Alberta, Sept. 25, 2026 (GLOBE NEWSWIRE) — Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, today announces the change of its Chief Executive Officer (CEO). Effective November 23, 2026, Dr. Madi Madiyalakan will be […]
View source ↗ - Newszacks.com·58d ago·Positive
Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally? DGX's 36.3% YTD rise reflects momentum in advanced diagnostics, channel growth, AI adoption and cost savings.
View source ↗ - News (RSS)seekingalpha·60d ago·Positive
Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds
View source ↗ - Newsseekingalpha.com·60d ago·Positive
…iagnostics. Their dialysis testing and advanced diagnostics add growth opportunities, although their value ultimately depends on execution and reimbursement. So far, DGX's cash flows seem to be benefiting from the acquisition strategy, but if this falters, it may lead to write-downs of its sizable goodwill on the balance sheet.
View source ↗ - Newsprnewswire.com·61d ago·Neutral
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026 SECAUCUS, N.J., Sept. 22, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its third quarter 2026 financial results on Thursday, October 22, 2026, before the market opens.
View source ↗ - News (RSS)zerohedge·61d ago·Neutral
…ssion. Grab (GRAB) rises 6% after Chief Executive Officer Anthony Ping Yeow Tan disclosed a $29.9 million stock purchase in a filing with the SEC. Quest Diagnostics (DGX) falls 6% after the Centers for Medicare & Medicaid Services released new preliminary medicare payment rates for lab services. Vicor (VICR) jumps 9% after the power equipment company raised its third-quarter revenue growth guidance, citing royalties from non-exclusive license to Vertical Power Delivery. Viking Therapeutics (VKTX…
View source ↗ - Newszacks.com·61d ago·Positive
Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure DGX study finds nearly one-third of Lyme-seropositive patients had antibodies to another tick-borne pathogen, highlighting broader testing needs.
View source ↗ - Newszacks.com·61d ago·Positive
Is This the Right Time to Add DGX Stock to Your Portfolio? Quest Diagnostics gains momentum from customer wins, advanced diagnostics and AI initiatives, while reimbursement uncertainty, costs and debt pose challenges.
View source ↗ - News (RSS)investing·61d ago·Neutral
Why is Quest Diagnostics stock sliding today?
View source ↗ - Newsmarketbeat.com·62d ago·Positive
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges Quest Diagnostics NYSE: DGX CEO and President Jim Davis said the diagnostic testing company is exceeding the growth framework it outlined at its prior investor day, driven largely by organic growth, consumer-health demand and partnerships rather than a heavier-than-expected pace of acquisitions.
View source ↗ - Newsprnewswire.com·62d ago·Positive
Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics Study published in JAMA Network Open of over 193,000 patients nationwide reveals that individuals with evidence of exposure to Borrelia burgdorferi, the bacterium that causes Lyme disease, are more than four times as likely to have antibodies against other tick-borne pathogens compared to those without. SECAUCUS, N.J.
View source ↗ - Newsprnewswire.com·67d ago·Negative
Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics 75% of registered voters surveyed call diagnostic testing "very important" to their care, and a bipartisan majority wants Congress to pass the RESULTS Act before additional Medicare cuts are scheduled to take effect January 2027 SECAUCUS, N.J., Sept. 16, 2026 /PRNewswire/ -- A new national survey finds the overwhelming majority of Amer…
View source ↗ - News (RSS)investing·68d ago·Neutral
Quest Diagnostics stock hits all-time high at $247.3
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Quest Diagnostics Incorporated (DGX) Presents at 2026 Global Healthcare Conference Transcript Quest Diagnostics Incorporated (DGX) Presents at 2026 Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·69d ago·Positive
Quest Diagnostics (DGX) is a Top-Ranked Momentum Stock: Should You Buy? Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - News (RSS)bbc·73d ago·Positive
'We never recovered him': Quest to identify remains from Ground Zero continues Since the attacks, New York officials are working with new, complex technology to find traces of more than 1,000 victims.
View source ↗ - News (RSS)investing·74d ago·Neutral
Quest to offer lab testing through Apple Health app for $119
View source ↗ - News (RSS)fool·75d ago·Negative
Quest Diagnostics CEO Sells 10,000 Shares for $2.4 Million J. E. Davis disposed of 8% of his direct equity stake under a pre-planned Rule 10b5-1 trading arrangement, retaining $28.9 million in company stock.
View source ↗ - 4chan /biz/biz·79d ago·Neutral
>>62659986 What's the ticker for DGX?
View source ↗ - 4chan /biz/biz·79d ago·Neutral
>DGX Spark went up 28% over night >Nvidia only up 1% How is this legal?
View source ↗ - News (RSS)venturebeat·82d ago·Neutral
…tic platform, arrived in March 2026, followed by desktop apps for Mac and Windows. Just last week, the company launched a local-first version of Computer on NVIDIA's DGX Spark hardware, which starts on the user's device and escalates to cloud models only with permission. Today's launch inverts that flow: cloud-first, delegating down.The business trajectory has been equally steep. Perplexity was valued at $520 million in January 2024; by September 2025, the company had finalized a funding round a…
View source ↗ - Newszacks.com·83d ago·Positive
Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy? The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - News (RSS)zerohedge·86d ago·Negative
…r millions of families navigating the uncertainty of Alzheimer's disease, a timely diagnosis is the first and most critical step toward meaningful care." Labcorp and Quest Diagnostics said they will carry the new test. Once ordered by a doctor, patients can have their blood drawn for the test in a doctor's office, a Labcorp service center, or a Quest center. Tyler Durden Thu, 08/27/2026 - 23:00
View source ↗ - Newsprnewswire.com·87d ago·Neutral
Quest Global renforce son partenariat stratégique avec Babcock grâce à un accord-cadre quinquennal portant sur des services d'ingénierie groupés /PRNewswire/ -- Quest Global Engineering Services Limited, l'une des plus grandes sociétés indépendantes spécialisées exclusivement dans les services
View source ↗ - News (RSS)nyt·88d ago·Negative
Bessent Faces Credibility Test in Quest to Tame Markets The Treasury secretary is confronting the limits of his ability to reshape the economy ahead of midterm elections.
View source ↗ - News (RSS)venturebeat·89d ago·Neutral
…rplexity is launching Portable Computer today, a version of its agentic "Computer" platform that runs entirely on hardware users already own — starting with Nvidia's DGX Spark desktop supercomputer and Linux machines equipped with Nvidia RTX GPUs.The launch, developed in close partnership with Nvidia, is one of the most aggressive attempts yet to move serious AI agent workloads off the cloud and onto local devices. The model, the user's files, and the work itself can all stay on the machine. Wor…
View source ↗ - Newsprnewswire.com·89d ago·Positive
…sumer-initiated testing platform LONDON, Aug. 25, 2026 /PRNewswire/ -- Humanity Health Inc. ("Humanity"), the longevity science company, and Quest Diagnostics (NYSE: DGX) today announced that Humanity Biological Age, Humanity's scientifically validated model for measuring biological age from biomarker lab test results, is now available in the United States for the first time through questhealth.com, Quest's consumer-initiated testing platform. Individuals now have the option to select the Humani…
View source ↗ - News (RSS)zerohedge·92d ago·Neutral
A Call To Power: Islamic Leaders See Ballot Box As Path To Paradise A Call To Power: Islamic Leaders See Ballot Box As Path To Paradise Authored by Paul Sperry via RealClearInvestigations, The call to prayer is sounding across America. From Hamtramck, Michigan, to Paterson, New Jersey, to Minneapolis, Minnesota, rooftop amplifiers remind growing numbers of Muslim faithful five times a day of their duties with the Arabic message that "Allah is the Greatest! There is no god but Allah!" The so-call
View source ↗ - Newszacks.com·93d ago·Neutral
Is it the Right Time to Retain DGX Stock in Your Portfolio? Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.
View source ↗ - Newszacks.com·93d ago·Positive
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue? Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
View source ↗ - Newszacks.com·96d ago·Positive
Quest Diagnostics (DGX) Upgraded to Buy: Here's Why Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - News (RSS)venturebeat·96d ago·Positive
…al becomes clearer when the model is compressed. Developer and AI writer Simon Willison tested a roughly 17GB Q4_K_M quantization on an M5 Max MacBook Pro and Nvidia DGX Spark. He found that it could write code, interpret images and operate a coding-agent loop through the Pi agent framework. In one experiment, the model navigated a codebase to explain how authentication worked; in another, it wrote and tested a Python utility Willison needed to convert an agent transcript from JSONL to Markdown.…
View source ↗ - Newszacks.com·97d ago·Positive
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·100d ago·Neutral
Quest Diagnostics (DGX) Is Up 2.29% in One Week: What You Should Know Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newsprnewswire.com·102d ago·Negative
Quest Diagnostics Declares Quarterly Cash Dividend SECAUCUS, N.J., Aug. 12, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October 21, 2026 to shareholders of record of Quest Diagnostics common stock on October 6, 2026.
View source ↗
Earnings
Tue, Feb 9(in 3 months)
Consensus estimate $2.68 per share
Typical surprise +4.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 22$3.00 vs $2.87beat
- Thu, Jul 23$3.12 vs $2.82beat
- Tue, Apr 21$2.50 vs $2.37beat
- Tue, Feb 10$2.42 vs $2.36beat
- Tue, Oct 21$2.60 vs $2.50beat
- Tue, Jul 22$2.62 vs $2.57beat
Estimates and results for DGX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DGX officers and directors.
- Bought
- —
- Sold
- $23.5m
0 trades
21 trades
- Deppe Michael Jsold
- Plewman Patricksold
- Plewman Patricksold
- Doherty Catherine T.sold
- Doherty Catherine T.sold
- Doherty Catherine T.sold
- Doherty Catherine T.sold
- Doherty Catherine T.sold
79 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (33d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (35d later)Buy$1,001 - $15,000
- Carol Devine Millerhouse · WV01 · disclosed Aug 14, 2026 (522d later)Sell$15,001 - $50,000
- Julie Johnsonhouse · TX32 · disclosed Aug 6, 2026 (280d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Aug 6, 2026 (280d later)Buy$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (113d later)Buy$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (260d later)Buy$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (173d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Dec 12, 2025 (39d later)Sell$1,001 - $15,000
- Carol Devine Millerhouse · WV01 · disclosed Apr 11, 2025 (32d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Feb 12, 2025 (19d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2024 (21d later)Buy$1,001 - $15,000
- Earl Blumenauerhouse · OR03 · disclosed May 4, 2024 (30d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (22d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (22d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Feb 14, 2024 (42d later)Sell$15,001 - $50,000
- Thomas Richard Carpersenate · DE · disclosed Jan 3, 2024 (23d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (8d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 6, 2023 (30d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
